Home / Stocks / ZNTL

ZNTL insider trading

Zentalis Pharmaceuticals, Inc. — open-market insider buys and $1M+ sells from SEC Forms 3, 4 and 5.
Insider buys · 24 mo
7
Bought · 24 mo
$23.2M
Buys · last 90 days
1 · $15.2M
Most recent buy
2026-08-19

Cluster buy detected

4 insiders bought ZNTL within a short window (2025-01-31→2025-02-06), $223k in total — cluster score 70/100. Members see the buyers, the score breakdown and the chart.

See the cluster

Recent insider filings

FiledInsiderTypeSharesPriceValue
2026-08-19WALTERS GROUP
10% owner
Bought4,335,000$3.50$15.2M
2026-01-08WALTERS GROUP
10% owner
Bought6,459,973$1.20$7.8M
2025-12-15GOEL DAVID E.
10% owner
Sold7,500,000$1.33$10.0M
2025-04-30Myers Scott Dunseth
Director
Bought21,000$1.40$29k
2025-02-12Bruns Ingmarcluster
Chief Medical Officer
Bought20,000$2.28$46k
2025-02-04Skvarka Jancluster
Director
Bought60,000$1.72$103k
2025-02-04Walker Luke Nathanielcluster
Director
Bought14,200$1.76$25k
2025-02-04EASTLAND JULIA MARIEcluster
CEO & President
Bought28,500$1.73$49k

Most active insider buyers

InsiderRoleBuysTotal bought
WALTERS GROUP10% owner2$22.9M
Skvarka JanDirector1$103k
EASTLAND JULIA MARIECEO & President1$49k
Bruns IngmarChief Medical Officer1$46k
Myers Scott DunsethDirector1$29k
Walker Luke NathanielDirector1$25k

See ZNTL on the chart

Every insider buy and sell for ZNTL plotted on the price, the full two-year history, cluster scores and daily updates — in the members area, $29/month. A free quarterly sample of the whole dataset needs no account.

Open the browserFree sample
Data from the SEC EDGAR ownership filings, refreshed daily. Only open-market purchases (transaction code P) and sales of $1M or more are shown; grants, option exercises and tax withholding are excluded because they run on schedules set years earlier. Not investment advice.